Client of a consultant lobbyist
Apotex Inc.
- Meetings this Parliament
- 4
- With MPs
- 0
- Since Nov 2021
- 9
- Active registrations
- 0
Most recent reported meeting: Nov 6, 2025.
Lobbying by Apotex Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Apotex Inc. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Dario Dimitriev · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dario Dimitriev · Consultant
- Jessica Fullerton · Senior Policy Advisor, Finance Canada (FIN)
- Mackenzy Metcalfe · Policy advisor, Finance Canada (FIN)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dario Dimitriev · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dario Dimitriev · Consultant
- Galen Richardson · Stakeholder Relations Advisor, Intergovernmental Affairs Secretariat (IGA)
- Miro Froehlich · Director of Policy, Intergovernmental Affairs Secretariat (IGA)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dario Dimitriev · Consultant
- Matthew O'Connell · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Roy Karam · Director of Operations, Health Canada (HC)
- Stephanie Claxton · Director of Policy, Health Canada (HC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dario Dimitriev · Consultant
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health
-
Reported by Dario Dimitriev · Consultant
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Economic DevelopmentHealth
-
Reported by Dario Dimitriev · Consultant
- Zachary Nixon · Senior Advisor, Global Affairs Canada (GAC)
International Trade
-
Reported by Dario Dimitriev · Consultant
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.